A clinical trial found that aspirin treatment significantly reduced the risk of thrombosis, cardiovascular death, and minor bleeding events in patients with polycythemia vera. The study suggests that aspirin can be a safe and effective treatment option for these patients.
A phase II trial found that AMD-3100, a new drug, increases the availability of stem cells in cancer patients undergoing transplantation. This boosts the chances of successful transplantation and may reduce the number of collections needed.
A new direct thrombin inhibitor, ximelagatran, has shown promising results in preventing recurrent venous thromboembolism in patients with acute deep vein thrombosis. The study found that oral ximelagatran was as effective as enoxaparin/warfarin in preventing this condition, while also reducing major bleeding and mortality rates.
Researchers identified three strongly predictive genes - OPAL1, GNB2L1, and IL-10 receptor alpha - that were associated with better outcomes in pediatric ALL patients. These genes may help improve risk classification and outcome prediction for acute leukemia in children.
The study found that adding rituximab to the CHOP regimen as a first-line treatment did not significantly impact overall response rates or early disease progression. Maintenance rituximab showed promise in prolonging time-to-treatment failure, but had no effect on overall survival.